Showing results (721-730 of 782) with videos related to

Sort By:
Pageof 79
Blood|July 15, 2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaPaul G Richardson, Emily Blood, Constantine S Mitsiades, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2018
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple MyelomaJacob P Laubach, Chia-Jen Liu, Noopur S Raje, et al.
British Journal of Haematology|May 4, 2017
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myelomaJacob P Laubach, Javid J Moslehi, Sanjeev A Francis, et al.
The New England Journal of Medicine|June 3, 2015
Elotuzumab Therapy for Relapsed or Refractory Multiple MyelomaSagar Lonial, Meletios Dimopoulos, Antonio Palumbo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2013
Multiple myeloma, version 1.2013Kenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 19, 2009
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemiaAkinori Yoda, Yuka Yoda, Sabina Chiaretti, et al.
Blood|August 30, 2003
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysisFaith E Davies, Ann M Dring, Cheng Li, et al.
Blood|March 22, 2021
miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasmsTomasz Sewastianik, Juerg R Straubhaar, Jian-Jun Zhao, et al.
British Journal of Haematology|November 16, 2012
Response assessment in Waldenström macroglobulinaemia: update from the VIth International WorkshopRoger G Owen, Robert A Kyle, Marvin J Stone, et al.
Leukemia|September 19, 2025
The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myelomaJulia Frede, Julia C Poller, Kayleen Shi, et al.
Pageof 79